Video: Meet Our Representatives

Home > Patient Support > Educational Materials >

Meet Our Representatives

Meet Steve, Jesús, and Tom, 3 Novo Nordisk Representatives who work directly with the hemophilia community. Hear about how Novo Nordisk has committed to addressing the community’s unique needs and how much they enjoy their role in helping to improve the lives of people living with hemophilia.

Play

Pause

Skip

Volume

Chapters

Transcript

References

video_su

Fullscreen

Meet Our Representatives

Share:

Email a link

Chapters

Transcript

References

Return to overview

Chapters

Return to overview

Transcripts

Return to overview

References

Available from Novo Nordisk:

Visit website | Prescribing Information

What is Esperoct^®?

Esperoct^® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct^® when you have surgery

Esperoct^® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Esperoct^®?

You should not use Esperoct^® if you are allergic to factor VIII or any of the other ingredients of Esperoct^® or if you are allergic to hamster proteins

What is the most important information I need to know about Esperoct^®?

Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What should I tell my healthcare provider before using Esperoct^®?

Before taking Esperoct^®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
Your body can make antibodies called “inhibitors” against Esperoct^®, which may stop Esperoct^® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct^®

What are the possible side effects of Esperoct^®?

Common side effects of Esperoct^® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Esperoct^® Prescribing Information.

Esperoct^® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-10881-800-FDA-1088.

What is Novoeight^®?

Novoeight^® (antihemophilic factor, recombinant) is an injectable medicine used to control and prevent bleeding in people with hemophilia A. Your healthcare provider may give you Novoeight when you have surgery

Novoeight^® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Novoeight^®?

You should not use Novoeight^® if you are allergic to factor VIII or any of the other ingredients of Novoeight^® or if you are allergic to hamster proteins

What is the most important information I need to know about Novoeight^®?

Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia center
Call your healthcare provider right away and stop treatment if you get any of the following signs of an allergic reaction: rashes or hives, difficulty breathing or swallowing, tightness of the chest, swelling of the lips and tongue, light-headedness, dizziness or loss of consciousness, pale and cold skin, fast heartbeat, or red or swollen face or hands

What should I tell my healthcare provider before using Novoeight^®?

Before taking Novoeight^®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
Your body can make antibodies called “inhibitors” against Novoeight^®, which may stop Novoeight^® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Novoeight^®

What are the possible side effects of Novoeight^®?

Common side effects of Novoeight^® include inhibitors in patients who were not previously treated with factor VIII products, swelling or itching at the location of injection, and fever

Please click here for Novoeight^® Prescribing Information.

Novoeight^® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-10881-800-FDA-1088.

Novo Nordisk, Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.

Esperoct^® and Novoeight^® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Novo Nordisk^Â®

Prescribing Novoeight^®? Consider Esperoct^®.

If you like the efficacy and fixed dosing of Novoeight (antihemophilic factor, recombinant), take a look at Esperoct^® for your hemophilia A patients. With a longer half-life across age groups than standard half-life FVIII products, Esperoct^® could be right for your patients.^1,a,b

Please click here for Esperoct^®Prescribing Information

Please click here for Novoeight^®Prescribing Information

^aA phase 1, open-label study evaluated the safety and pharmacokinetic properties of Esperoct^® in 26 PTPs. Patients received a single dose of 25, 50, or 75 IU/kg of their previous SHL product (pdFVIII or rFVIII), followed by the same dose of Esperoct^®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.¹

^bIn a phase 3 study of children (aged <12 years) a single-dose PK comparison was performed in 27 children between previous SHL products and Esperoct^® at the same administered dose prior to the start of routine prophylaxis. Half-life comparison is based upon the estimated half-life derived from a population-based model. During the main phase, 68 children received prophylaxis at an average dose of approximately 65 IU/kg twice weekly for 26 weeks.²

References:

Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670-678.
Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117:1705-1713.

Explore Esperoct^®

Continue to Novoeight^®

Novoeight®

[Antihemophilic Factor (Recombinant)]

Meet Our Representatives